Succimer is an orally active chelating agent that is worthy of consideration in children with elevated blood lead concentrations and without encephalopathy.
In the short term, it appears well tolerated and has similar efficacy to other agents used in mild to moderate lead poisoning.
As with other agents, succimer produces a rapid reduction in blood lead concentrations during therapy, but concentrations rebound towards pretreatment values following discontinuation of the drug. Experience with the drug is limited and it has not been evaluated in children with encephalopathy, for whom other agents are preferred.
For less serious cases of lead poisoning, succimer cannot be routinely recommended in place of more established agents. Rather, physicians should consider likely efficacy, contraindications, patient preference, blood lead concentrations and personal experience with the available agents on an individual basis.